Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase I/II Radioimmunotherapy of Non-Hodgkin's Lymphoma With Radiolabeled Humanized Immuno-LL2: Treatment With 90Y-hLL2 IgG.

Next Previous
X
Search
Trial Profile

Phase I/II Radioimmunotherapy of Non-Hodgkin's Lymphoma With Radiolabeled Humanized Immuno-LL2: Treatment With 90Y-hLL2 IgG.

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 23 Aug 2021

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Epratuzumab Y-90 (Primary)
  • Indications Non-Hodgkin's lymphoma
  • Focus Adverse reactions
  • Sponsors Gilead Sciences; Immunomedics

    • Most Recent Events

    • 15 Jun 2009 Results have been presented at the 56th Annual Meeting of the Society of Nuclear Medicine (2009), as reported in an Immunomedics media release. Actual patient number updated (n=64).
    • 17 Jan 2008 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 11 Jun 2007 Interim results were presented at the 12th Congress of the European Hematology Association in June 2007 (9076809).

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top